Type of Cancer
Phase
Division (Location)
Study ID
NCT#
Brief Description
A Phase 1b/2 Open-Label, Dose Escalation and Expansion Study of Orally Administered VRx-3996 and Valganciclovir in Subjects with Epstein-Barr Virus-Associated Lymphoid Malignancies
To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.